Direct oral anticoagulants: An alternative treatment for thrombotic antiphospholipid syndrome?

Lupus

Volumn 26, Issue 12, 2017, Pages 1297-1303

  Resseguier, A S ^a   Pereira, B ^b   Rieu, V ^a   Le Guenno, G ^a   Grobost, V ^a   Ruivard, M ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Anticoagulation; antiphospholipid syndrome; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; CREATININE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; MYCOPHENOLATE MOFETIL; PHOSPHATIDYLETHANOLAMINE; RIVAROXABAN; STEROID; ANTICOAGULANT AGENT;

ADULT; ALTERNATIVE MEDICINE; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBOLISM PREVENTION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; IRON DEFICIENCY ANEMIA; LEG PAIN; LUNG EMBOLISM; MALE; MIDDLE AGED; NAUSEA; NEUROFIBROMATOSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PILOT STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT REFUSAL; VEIN THROMBOSIS; VERTIGO; YOUNG ADULT; COMPLICATION; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; THROMBOSIS;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PILOT PROJECTS; PULMONARY EMBOLISM; RIVAROXABAN; THROMBOSIS; YOUNG ADULT;

EID: 85021733216     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203317701841     Document Type: Article

References (38)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13: 685-696.
3. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
4. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-853.
5. Da Silva FF, Carvalho JF,. Intensity of anticoagulation in the treatment of thrombosis in the antiphospholipid syndrome: a meta-analysis. Rev Bras Reumatol 2015; 55: 159-166.
6. Crowl A, Schullo-Feulner A, Moon JY,. Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant. Ann Pharmacother 2014; 48: 1479-1483.
7. EINSTEIN Investigators. Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
8. EINSTEIN Investigators. Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
9. Büller HR, Décousus H, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
10. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
11. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
12. Arachchillage DJ, Cohen H,. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 2013; 15: 331-331.
13. Moerloose P, Reber G, Musial J, Arnout J,. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost 2010; 8: 1540-1506.
14. Fontana P, Poncet A, Lindhoff-Last E, et al. Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. J Thromb Haemost 2014; 12: 2034-2037.
15. Pengo V, Tripodi A, Reber G, et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1737.
16. Ratain MJ, Sargent DJ,. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009; 45: 275-280.
17. Lim W, Crowther MA, Eikelboom JW,. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295: 1050-1057.
18. Cohen H, Hunt B, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non inferiority trial. Lancet Haematol 2016; 3: 426-436.
19. Noel N, Dutasta F, Costedoat-Chalumeau N, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 2015; 14: 680-685.
20. Sciascia S, Savino S, Breen K, Hunt BJ,. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis Int J Haemost Thromb 2015; 26: 476-477.
21. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A,. The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. Thromb Res 2015; 135: 1035-1036.
22. Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE,. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 2014; 112: 947-950.
23. Win K, Rodgers GM,. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 2014; 89: 1017-1017.
24. Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA,. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 2016; 35: 801-805.
25. Betancur JF, Bonilla-Abadía F, Hormaza AA, Jaramillo FJ, Cañas CA, Tobon GJ,. Direct oral anticoagulants in antiphospholipid syndrome: a real-life case series. Lupus 2016; 25: 658-662.
26. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74: 1011-1018.
27. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-242.
28. Pengo V, Banzato A, Bison E, Zoppellaro G, Padayaltil Jose S, Denas G,. Efficacy and safety of Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in Antiphospholipid Syndrome (TRAPS) trial. Lupus 2016; 25: 301-306.
29. Woller SC, Stevens SM, Kaplan DA, et al. Apixaban for the Secondary Prevention of Thrombosis Among Patients with Antiphospholipid Syndrome: study rationale and design (ASTRO-APS). Clin Appl thromb Haemost 2016; 22: 239-247.
30. Prins MH, Bamber L, Cano SJ, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015; 135: 281-288.
31. Pastori D, Parrotto S, Vicario T, et al. Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. Atherosclerosis 2016; 244: 48-50.
32. Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J 2015; 170: 675-682, e8.
33. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413-2424.
34. Hara T, Fukuda D, Tanaka K, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015; 242: 639-646.
35. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
36. Berkner KL, Runge KW,. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost 2004; 2: 2118-2132.
37. Schurgers LJ, Joosen IA, Laufer EM, et al. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PloS One 2012; 7: e43229-e43229.
38. Levy RA, Signorelli F,. Patient-health care provider relationship: how can it impact on APS (Hughes' syndrome) adherence to treatment? Lupus 2014; 23: 1265-1268.